Breast Cancer (2017) 24:658–666 DOI 10.1007/s12282-017-0752-5 ORIGINAL ARTICLE The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro 1 1 1 • • Satoshi Tanaka Kanayo Suzuki Minoru Sakaguchi Received: 3 October 2016 / Accepted: 3 January 2017 / Published online: 9 January 2017 The Japanese Breast Cancer Society 2017 Abstract (CDK4), E2F1, and retinoblastoma protein (pRb) expres- Background Prolyl oligopeptidase (POP, EC 220.127.116.11) is a sion; and increased cyclin-dependent kinase inhibitor 1B kip1 serine peptidase that hydrolyzes post-proline peptide bonds (p27 ) expression. Moreover, the SUAM-14746-medi- in peptides that are \30 amino acids in length. We previ- ated cell cycle arrest of MCF7 cells was associated with ously reported that POP inhibition suppressed the growth increased pRb2/p130 protein expression and an increase in of NB-1 human neuroblastomas cells and KATO III human the number of cells in the quiescent G state, as deﬁned by gastric cancer cells. POP activity is commonly elevated in low RNA levels. many cancers, which includes breast cancer. However, the Conclusions SUAM-14746 inhibited breast cancer cell effect of POP inhibition as a candidate breast cancer growth in a cytostatic manner without inducing lethality, therapy is unknown. and POP-speciﬁc
Breast Cancer – Springer Journals
Published: Jan 9, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud